- $6.73bn
- $7.57bn
- $1.48bn
Brief: Alkermes Announces Initiation Of Vibrance-1 Phase 2 Study Evaluating ALKS 2680 For Treatment Of Narcolepsy Type 1
Brief: Alkermes Announces Initiation Of Vibrance-1 Phase 2 Study Evaluating ALKS 2680 For Treatment Of Narcolepsy Type 1
Alkermes Plc expected to post earnings of 60 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Chemours, Lucid, OppFi
U.S. STOCKS ON THE MOVE-Digital Realty, Alphabet, Moderna
U.S. STOCKS ON THE MOVE-Bloom Energy, Hecla Mining, Alkermes
Alkermes' sleep disorder drug shows promise in early-stage study
Brief: Alkermes Announces Positive Topline Results From Phase 1B Study Of ALKS 2680
Brief: Alkermes PLC Increases Size Of Board
U.S. STOCKS ON THE MOVE-Super Micro, Albemarle
Alkermes rises on Q4 revenue estimates beat
Alkermes Plc reports results for the quarter ended in December - Earnings Summary
Brief: Alkermes PLC Reports Financial Results For The Fourth Quarter And Year Ended Dec. 31, 2023 And Provides Financial Expectations For 2024
Alkermes Plc expected to post earnings of 51 cents a share - Earnings Preview
Brief: Alkermes PLC On Feb 1, Designated Blair C. Jackson As Co's Interim Principal Financial Officer
Brief: Alkermes Announces Topline Results From Long-Term, Open-Label Safety and Durability of Treatment Effect Study of LYBALVI
Brief: Alkermes Announces Agreement To Sell Athlone, Ireland Facility To Novo Nordisk
Brief: Alkermes Announces Agreement To Sell Ireland Facility To Novo Nordisk
Brief: Alkermes PLC Reduced Size Of Board From Eleven To Ten Directors